Cargando…

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

INTRODUCTION: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization’s elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreoni, Massimo, Di Perri, Giovanni, Persico, Marcello, Marcellusi, Andrea, Ethgen, Olivier, Sanchez Gonzalez, Yuri, Bondin, Mark, Zhang, Zhenzhen, De Michina, Antonella, Merolla, Rocco Cosimo Damiano, Craxì, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925258/ https://www.ncbi.nlm.nih.gov/pubmed/33655410 http://dx.doi.org/10.1007/s40121-021-00410-0

Ejemplares similares

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
por: Aghemo, Alessio, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
por: Back, David, et al.
Publicado: (2019)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions
por: Kondili, Loreta A., et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
por: Jonas, Maureen M., et al.
Publicado: (2021)

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
por: Yamana, Yoichiro, et al.
Publicado: (2021)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
por: Feld, Jordan J., et al.
Publicado: (2022)

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
por: Forns, Xavier, et al.
Publicado: (2021)

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
por: Fontana, Robert J., et al.
Publicado: (2019)

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
por: Flamm, Steven, et al.
Publicado: (2018)

Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir
por: Totsuka, Mai, et al.
Publicado: (2021)

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
por: Martinello, Marianne, et al.
Publicado: (2023)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
por: Shen, Chao, et al.
Publicado: (2020)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C
por: Fansiwala, Kush, et al.
Publicado: (2021)

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria
por: Schmidbauer, Caroline, et al.
Publicado: (2020)

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation
por: Marcellusi, Andrea, et al.
Publicado: (2021)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
por: Toyoda, Hidenori, et al.
Publicado: (2017)

1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks
por: Sarrazin, Christoph, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ch89isafr1ct6r3claphiop4ie